[在儿童中治疗困难菌感染的进展]
Yu Gan1, Zhi-Hong Wu1, Qian-Long Li2
1Department of Gastroenterolog, Xiangya Hospital, Central South University, Changsha 410008, China (Lu Z-X, Email: 3867903@163. com).
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
|September 13, 2024
概括
儿童困难菌感染 (CDI) 在抗生素治疗后经常复发. 便微生物群移植为儿童复发性CDI提供了安全有效的替代方案.
科学领域:
- 胃肠病学 胃肠病学
- 儿童传染病 儿童传染病
- 微生物组研究 微生物组研究
背景情况:
- 困难菌感染 (CDI) 是儿童在医院获得的感染的重要原因.
- 小儿CDI的抗生素治疗可能导致复发,随后的抗生素治疗增加了进一步复发的风险.
- 复发性CDI需要探索标准抗生素之外的替代治疗策略.
研究的目的:
- 审查有关儿科CDI的发病,风险因素,诊断和治疗的当前研究.
- 突出便微生物群移植 (FMT) 作为儿科复发性CDI的治疗选择.
- 提供关于儿科CDI管理的国内和国际发现的概述.
主要方法:
- 关于儿童Clostridium difficile感染的最近研究的文献综述.
- 关于便微生物群移植在儿科群体中的疗效和安全性的数据分析.
- 综合有关CDI病原,风险因素和诊断方法的信息.
主要成果:
- 便微生物群移植 (FMT) 已在治疗复发性CDI方面表现出显著的疗效.
- 在为复发性CDI接受治疗的儿科患者中,FMT具有很高的安全性.
- 抗生素治疗仍然是主要的治疗方法,但与高复发率有关.
结论:
- 便微生物群移植是对患有复发性Clostridium difficile感染的儿童的有希望和安全的治疗选择.
- 需要进一步研究和临床应用FMT来管理耐火儿科CDI.
- 对于有效的治疗策略来说,全面了解CDI病原和风险因素至关重要.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:21Drugs for Treatment of Constipation-Predominant IBS
145
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
145
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
111
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
111
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153